ZIA BC 011479 (ZIA) | |||
---|---|---|---|
Title | T-cell receptor gene therapy for human papillomavirus-positive cancers | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Hinrichs, Christian | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $671,060 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Digestive Diseases (10.0%) Gene Therapy (75.0%) Gene Therapy Clinical Trials (75.0%) |
Anus (10.0%) Cervical Cancer (70.0%) Head and Neck (14.0%) Penis (2.0%) Pharynx (7.0%) Vaginal (2.0%) |
||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
We have isolated a high-affinity HLA-A2-restricted TCR against the HPV-16 E6 oncoprotein. This was accomplished by identifying from the metastatic tumor of a patient with anal cancer a T cell clone against the E6 29-38. The gene sequence of the TCR expressed by this clone was determined, and a retroviral expression vector encoding the TCR was generated. T cells transduced to express this TCR display high-avidity for the HPV-16 E6 29-38 epitope as well as specific recognition of HPV-16-positive tumor lines. A clinical trial testing adoptive transfer of autologous T cells transduced to express this TCR for the treatment of HPV-positive cancers has been completed. Data analysis is underway. In addition, we have identified a TCR targeting HPV-16 E7. A clinical trial of this TCR is also active. |